<DOC>
	<DOCNO>NCT01736176</DOCNO>
	<brief_summary>The primary objective study evaluate change non-motor symptom baseline Week 12 measure Non-Motor Symptom Scale total score .</brief_summary>
	<brief_title>A Study Assess Safety Efficacy Levodopa-carbidopa Intestinal Gel ( LCIG ) Treatment Non-motor Symptoms Patients With Advanced Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Subject must diagnosis idiopathic Parkinson 's disease ( PD ) accord United Kingdom Parkinson 's Disease Society ( UKPDS ) Brain Bank Criteria Demonstrate persistent motor fluctuation spite individually optimize treatment Subject must experience minimum 3 hour `` Off '' time Subject 's PD diagnosis unclear suspicion subject Parkinsonian syndrome secondary Parkinsonism ( e.g. , cause drug , toxin , infectious agent , vascular disease , trauma , brain neoplasm ) , Parkinsonplus syndrome ( e.g. , Multiple System Atrophy , Progressive Supranuclear Palsy , Diffuse Lewy Body Disease , Corticobasilar Degeneration ) , neurodegenerative disease might mimic symptom PD . Subject undergone neurosurgery treatment Parkinson 's disease Subject placement PEGJ tube LCIG treatment contraindicate consider high risk PEGJ procedure accord gastroenterology evaluation ( e.g. , pathological change gastric wall , inability bring gastric wall abdominal wall together , blood coagulation disorder , peritonitis , acute pancreatitis , paralytic ileus ) .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Safety efficacy</keyword>
	<keyword>Advanced Parkinson 's disease</keyword>
	<keyword>levodopa-carbidopa intestinal gel ,</keyword>
	<keyword>carbidopa</keyword>
	<keyword>levodopa</keyword>
	<keyword>Non-Motor Symptom Scale</keyword>
</DOC>